BHVN - Biohaven Pharmaceutical Holding Company Ltd.

NYSE - NYSE Delayed Price. Currency in USD
23.24
+1.47 (+6.75%)
At close: 4:02PM EST

23.24 0.00 (0.00%)
After hours: 4:48PM EST

Stock chart is not supported by your current browser
Previous Close21.77
Open21.75
Bid0.00 x 0
Ask0.00 x 0
Day's Range21.64 - 23.43
52 Week Range17.00 - 39.51
Volume482,144
Avg. Volume292,206
Market Cap837.049M
BetaN/A
PE Ratio (TTM)N/A
EPS (TTM)-6.24
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est38.00
Trade prices are not sourced from all markets
  • Biohaven Completes Enrollment In Second Pivotal Phase 3 Clinical Trial Of Oral CGRP-Receptor Antagonist Rimegepant
    PR Newswire17 days ago

    Biohaven Completes Enrollment In Second Pivotal Phase 3 Clinical Trial Of Oral CGRP-Receptor Antagonist Rimegepant

    NEW HAVEN, Conn., Nov. 27, 2017 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (BHVN) ("Biohaven" or the "Company") announced today completion of enrollment in Study BHV3000-302, the Company's second pivotal Phase 3 clinical trial examining the efficacy and safety of rimegepant in the acute treatment of migraine. The trial began shortly after the commencement of rimegepant's first efficacy trial, Study BHV3000-301, and the two trials enrolled simultaneously with the objective of announcing topline results for the migraine program in the first quarter of 2018.  Together the two pivotal trials enrolled approximately 3,000 subjects, which is expected to support a robust assessment of the efficacy of rimegepant in the acute treatment of migraine as required by the FDA for registration.

  • ACCESSWIRE23 days ago

    Featured Company News - Biohaven Pharma Completed Enrollment in First of Two Pivotal Phase-3 Clinical Trials of Rimegepant for Acute Treatment of Migraine

    Research Desk Line-up: Immunomedics Post Earnings Coverage LONDON, UK / ACCESSWIRE / November 20, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Biohaven ...

  • Biohaven Receives Agreement From FDA on Initial Pediatric Study Plan for Rimegepant, a Second Generation Oral CGRP-Receptor Antagonist for the Acute Treatment of Migraine
    PR Newswire24 days ago

    Biohaven Receives Agreement From FDA on Initial Pediatric Study Plan for Rimegepant, a Second Generation Oral CGRP-Receptor Antagonist for the Acute Treatment of Migraine

    NEW HAVEN, Conn., Nov. 20, 2017 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (BHVN) announced today that the Company has received agreement from the U.S. Food and Drug Administration (FDA) on the initial pediatric study plan (iPSP) for orally-dosed rimegepant. Rimegepant is a second-generation, small molecule, calcitonin gene-related peptide (CGRP) receptor antagonist being developed for the acute treatment of migraine.  Agreement on an iPSP is one of the regulatory requirements that must be met prior to submitting a new drug application (NDA).

  • Biohaven Completes Enrollment In The First Of Two Pivotal Phase 3 Clinical Trials Of Rimegepant, A Second Generation Oral CGRP-Receptor Antagonist, For The Acute Treatment Of Migraine
    PR Newswire28 days ago

    Biohaven Completes Enrollment In The First Of Two Pivotal Phase 3 Clinical Trials Of Rimegepant, A Second Generation Oral CGRP-Receptor Antagonist, For The Acute Treatment Of Migraine

    NEW HAVEN, Conn., Nov. 16, 2017 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (BHVN) announced that it is completing enrollment today in the first of its two registrational Phase 3 clinical trials, Study BHV3000-301, to establish the safety and efficacy of orally-dosed rimegepant.  Study BHV3000-301 has enrolled over 1,400 subjects since July 2017.  Rimegepant is a second generation, oral, calcitonin gene related peptide (CGRP) receptor antagonist being developed for the acute treatment of migraine. Rimegepant has composition of matter protection until 2030, not including patent term adjustment or any potential patent term extension. Rimegepant is one of only two small molecule CGRP-receptor antagonists in late stage clinical development.

  • Biohaven Pharmaceuticals Reports Third Quarter 2017 Financial And Business Results
    PR Newswire29 days ago

    Biohaven Pharmaceuticals Reports Third Quarter 2017 Financial And Business Results

    NEW HAVEN, Conn., Nov. 14, 2017 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (BHVN), a clinical-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological diseases, including rare disorders, today reported financial results for the quarter ended September 30, 2017, and provided a review of recent accomplishments and anticipated upcoming milestones.

  • Biohaven Expands Finance Team With Appointment Of Senior Vice President
    PR Newswirelast month

    Biohaven Expands Finance Team With Appointment Of Senior Vice President

    NEW HAVEN, Conn. , Nov. 13, 2017 /PRNewswire/ -- (NYSE: BHVN) - Biohaven Pharmaceutical Holding Company Ltd. ("Biohaven", or the "Company") and its wholly owned subsidiary, Biohaven ...

  • Biohaven Doses First Subject in Pivotal Bioequivalence Study with Sublingual BHV-0223
    PR Newswirelast month

    Biohaven Doses First Subject in Pivotal Bioequivalence Study with Sublingual BHV-0223

    NEW HAVEN, Conn., Nov. 6, 2017 /PRNewswire/ -- (BHVN) - Biohaven Pharmaceutical Holding Company Ltd. ("Biohaven" or the "Company") and its wholly owned subsidiary, Biohaven Pharmaceuticals, Inc., today announced that the first subject was dosed in its bioequivalence study designed to demonstrate the pharmacokinetic equivalence of sublingual BHV-0223 compared to Rilutek (riluzole). Biohaven is developing BHV-0223, a sublingual formulation of riluzole, as a potential treatment for patients with Amyotrophic Lateral Sclerosis (ALS).  Previously, the Company reported that the FDA had concluded its review of the investigational new drug (IND) application and notified   Biohaven that it may proceed with its clinical program.

  • Biohaven Announces FDA Clearance of IND Application for Sublingual BHV-0223 in Patients with Amyotrophic Lateral Sclerosis (ALS)
    PR Newswirelast month

    Biohaven Announces FDA Clearance of IND Application for Sublingual BHV-0223 in Patients with Amyotrophic Lateral Sclerosis (ALS)

    NEW HAVEN, Conn., Nov. 1, 2017 /PRNewswire/ -- (BHVN) - Biohaven Pharmaceutical Holding Company Ltd. (Biohaven or the "Company") and its wholly owned subsidiary, Biohaven Pharmaceuticals, Inc., today announced that the U.S. Food and Drug Administration (FDA) has notified the Company that it may proceed with its clinical investigation of sublingual BHV-0223 as a potential treatment for patients with Amyotrophic Lateral Sclerosis (ALS). The FDA clearance to proceed was received following Biohaven's submission of an investigational new drug (IND) application for this program, and the Company expects to commence a bioequivalence study of BHV-0223 in the current quarter. Biohaven previously received regulatory feedback from the FDA that the Section 505(b)(2) pathway is acceptable for BHV-0223 in ALS, and that beyond this study, no additional efficacy or toxicology studies will be necessary for the submission of a new drug application (NDA).

  • PR Newswirelast month

    Biohaven Announces First Patient Treated In Clinical Research Collaboration At Rutgers Cancer Institute

    NEW HAVEN, Conn., Oct. 30, 2017 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (Biohaven, NYSE: BHVN), a clinical-stage biopharmaceutical company, announced a clinical collaboration today with Drs. Ann Silk and James Goydos at the Rutgers Cancer Institute of New Jersey. Biohaven's glutamate modulating compound, trigriluzole, is being evaluated for safety in a Phase 1 trial in combination with PD-1 blocking antibodies in patients with inoperable, advanced or refractory cancers. Biohaven previously acquired the patent rights to develop and commercialize certain glutamate modulating agents for the treatment of cancer from Rutgers, The State University of New Jersey.

  • ACCESSWIRE2 months ago

    Corporate News Blog - US FDA Green Signals Clinical Investigation of Biohaven Pharma's Trigriluzole For Treatment Of OCD

    Research Desk Line-up: Illumina Post Earnings Coverage LONDON, UK / ACCESSWIRE / October 26, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Biohaven ...

  • PR Newswire2 months ago

    Biohaven Adds Clifford Bechtold as Chief Operating Officer

    Further Strengthens Company Leadership to Support Drug Development and Commercialization NEW HAVEN, Conn. , Oct. 25, 2017 /PRNewswire/ -- (NYSE: BHVN) - Biohaven Pharmaceutical Holding Company Ltd. ("Biohaven" ...

  • PR Newswire2 months ago

    Biohaven Receives FDA May Proceed Letter for Phase 2/3 Clinical Trial of Trigriluzole in Patients with Obsessive-Compulsive Disorder

    NEW HAVEN, Conn., Oct. 24, 2017 /PRNewswire/ -- (BHVN) Biohaven Pharmaceutical Holding Company Ltd. (Biohaven or the "Company") and its wholly owned subsidiary, Biohaven Pharmaceuticals, Inc., today announced that the U.S. Food and Drug Administration (FDA) has notified the Company that it may proceed with its clinical investigation of trigriluzole, a novel glutamate modulator, as a potential treatment for patients with obsessive-compulsive disorder (OCD). The FDA "May Proceed Letter" was received following Biohaven's filing of an investigational new drug (IND) application for this program, and the Company expects to commence a Phase 2/3 clinical trial of trigriluzole in OCD in the current quarter.

  • Why This Biotech Suffered A 2-Day Headache On Rare-Disease Trial
    Investor's Business Daily2 months ago

    Why This Biotech Suffered A 2-Day Headache On Rare-Disease Trial

    Biohaven continued its free fall after its rare-disease drug failed in a trial — prompting at least two stock downgrades.

  • Here's Why Biohaven Pharmaceutical Stock Fell as Much as 28.6% Today
    Motley Fool2 months ago

    Here's Why Biohaven Pharmaceutical Stock Fell as Much as 28.6% Today

    A lead product candidate failed in a phase 2/3 trial, but shares have recovered to a smaller loss.

  • Biohaven Reports Negative Topline Data from Spinocerebellar Ataxia (SCA) Phase 2/3 Trial
    PR Newswire2 months ago

    Biohaven Reports Negative Topline Data from Spinocerebellar Ataxia (SCA) Phase 2/3 Trial

    - Trigriluzole did not differentiate from placebo on the primary endpoint or key secondary outcome measure at the end of the 8-week randomization phase. - Placebo response rates in this study were higher than expected compared to prior European randomized controlled trials in SCA. - Trigriluzole was well tolerated and safely administered in this study population.

  • Biohaven And Alzheimer's Disease Cooperative Study (ADCS) Announce Phase 2 Clinical Trial Collaboration Evaluating Glutamate Modulating Agent Trigriluzole In Patients With Mild-To-Moderate Alzheimer's Disease
    PR Newswire3 months ago

    Biohaven And Alzheimer's Disease Cooperative Study (ADCS) Announce Phase 2 Clinical Trial Collaboration Evaluating Glutamate Modulating Agent Trigriluzole In Patients With Mild-To-Moderate Alzheimer's Disease

    NEW HAVEN, Conn., Sept. 15, 2017 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (BHVN), a clinical-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological diseases, announced today its clinical trial collaboration with the Alzheimer's Disease Cooperative Study (ADCS). The ADCS is a leading Alzheimer's disease (AD) clinical trials research consortium that receives major support from the U.S. National Institute on Aging (NIA), a part of the US National Institutes of Health.

  • Biohaven To Provide Development Program Update At The Morgan Stanley 15th Annual Global Healthcare Conference
    PR Newswire3 months ago

    Biohaven To Provide Development Program Update At The Morgan Stanley 15th Annual Global Healthcare Conference

    Biohaven remains on track, or ahead of timelines, in its clinical programs across its two primary technology platforms:  oral CGRP-receptor antagonists for patients with migraine, and oral glutamate modulators for patients with spinocerebellar ataxia (SCA) and other severe neurologic conditions that are related to glutamate dysregulation.

  • Biohaven Pharmaceuticals Reports Second Quarter 2017 Financial And Business Results
    PR Newswire4 months ago

    Biohaven Pharmaceuticals Reports Second Quarter 2017 Financial And Business Results

    NEW HAVEN, Conn., Aug. 14, 2017 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (BHVN), a clinical-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological diseases, including rare disorders, today reported financial results for the quarter ended June 30, 2017, and provided a review of recent accomplishments and anticipated upcoming milestones. "Biohaven continued to make significant progress in the second quarter of 2017 as we drive our development programs forward and prepare for the potential commercialization of multiple first-in-class and best-in-class products," said Vlad Coric, M.D., CEO of Biohaven.

  • Biohaven Completes Randomization In Phase 2/3 Trial In Spinocerebellar Ataxia: Expected Topline Data Advanced To Fourth Quarter Of 2017
    PR Newswire4 months ago

    Biohaven Completes Randomization In Phase 2/3 Trial In Spinocerebellar Ataxia: Expected Topline Data Advanced To Fourth Quarter Of 2017

    NEW HAVEN, Conn., Aug. 7, 2017 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (BHVN) announced today that it has commenced dosing of all 141 randomized patients with spinocerebellar ataxia (SCA) in its Phase 2/3 trial of trigriluzole (previously known as BHV-4157).  As a result, Biohaven now expects to receive topline results in the fourth quarter of 2017, earlier than previously expected.  Trigriluzole, a novel glutamate modulator, is a drug candidate being developed by Biohaven as a potential treatment for patients with SCA, a rare, debilitating, genetic neurodegenerative disorder that affects approximately 22,000 people in the United States. No medications are currently approved by the U.S. Food and Drug Administration (FDA) for the treatment of this devastating condition or any other cerebellar ataxias.

  • PR Newswire4 months ago

    Biohaven Appoints Julia P. Gregory to Board of Directors

    NEW HAVEN, Conn., Aug. 4, 2017 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (BHVN) today announced the appointment of Julia P. Gregory, M.B.A., to its Board of Directors. "We are thrilled to have Julia Gregory join Biohaven's Board of Directors. Ms. Gregory is an industry veteran and proven leader who has built an impressive track record in leading and advising biotechnology companies over her decades-long career.

  • PR Newswire4 months ago

    Biohaven Initiates Second Pivotal Phase 3 Clinical Trial of Oral CGRP Antagonist for the Acute Treatment of Migraine

    NEW HAVEN, Conn , July 31, 2017 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) announced today that it has commenced enrollment in the second of its two registrational Phase ...

  • Biohaven Enrolls First Patient in Pivotal Phase 3 Clinical Trial of Oral Rimegepant for the Acute Treatment of Migraine
    PR Newswire5 months ago

    Biohaven Enrolls First Patient in Pivotal Phase 3 Clinical Trial of Oral Rimegepant for the Acute Treatment of Migraine

    NEW HAVEN, Conn., July 24, 2017 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (BHVN) announced today that it has commenced enrollment in the first of its two registrational Phase 3 clinical trials to evaluate the safety and efficacy of orally-dosed rimegepant (BHV-3000) for the acute treatment of migraine. Biohaven expects to begin enrollment in the second Phase 3 clinical trial this summer and report topline results for both studies in the first half of 2018. Biohaven plans to conduct two double-blinded, placebo-controlled Phase 3 clinical trials to evaluate the efficacy and safety of 75 mg of rimegepant, Biohaven's innovative, orally-dosed small molecule CGRP receptor antagonist, for the acute treatment of migraine.

  • PR Newswire5 months ago

    PeptiDream and Kleo Pharmaceuticals Announce Collaboration Agreement to Develop Novel Immunotherapies for Oncology

    Under the terms of the agreement, PeptiDream will use its proprietary Peptide Discovery Platform System ("PDPS") technology to identify macrocyclic/constrained peptides against multiple oncology targets of interest selected by Kleo, and to optimize hit peptides into optimized binders that will be engineered by Kleo into novel ARM and SyAM products. Kleo will receive an upfront payment and will have the right to develop and commercialize all compounds resulting from the collaboration.

  • Biohaven Receives Notice Of Allowance From U.S. Patent And Trademark Office On Patent Application For Glutamate Modulating Prodrugs
    PR Newswire5 months ago

    Biohaven Receives Notice Of Allowance From U.S. Patent And Trademark Office On Patent Application For Glutamate Modulating Prodrugs

    A prodrug is a compound that, after administration, is metabolized in the body into an active drug. The prodrug design and selection pathways pursued by Biohaven are intended to address limitations of the active metabolite of a drug.